Bay Street News

Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019

March 1, 2019
- NASDAQ Companies
  0
ShareTweet
ShareTweet
» View More News for March 01, 2019

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search